Latest Roche Stories
PATERSON, N.J., May 18, 2011 /PRNewswire/ -- Children at Paterson Public School No.
LEUVEN, Belgium and LUND, Sweden, May 16, 2011 /PRNewswire-FirstCall/ -- - Two New Studies Now Ongoing: Phase Ib/II in Patients With Aggressive Brain Tumour and Phase Ib in Primary Liver Cancer ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
NUTLEY, N.J., May 5, 2011 /PRNewswire/ -- Susan Graf, of Nutley, N.J., Global Head of Strategic Evaluation and Due Diligence in Roche Partnering, was honored as a 2011 Rising Star by the Healthcare Businesswomen's Association (HBA) at the organization's annual awards luncheon today in New York City.
NUTLEY, N.J., May 5, 2011 /PRNewswire/ -- Two Roche employees are being recognized for their significant contributions to industry in New Jersey at the 37th Annual TWIN Awards Dinner held May 5, 2011.
PRINCETON, N.J., April 25, 2011 /PRNewswire/ -- Pharmasset, Inc.
ATLANTIC CITY, N.J., April 8, 2011 /PRNewswire/ -- Hagens Berman LLP, a nationally recognized law firm today praised a jury's verdict that ordered pharmaceutical company Roche (ROG:VX) to pay $2 million to a woman who suffered serious gastrointestinal damage caused by the drug Accutane, while denying similar claims of actor James Marshall and another plaintiff.
NUTLEY, N.J., March 28, 2011 /PRNewswire/ -- Roche announced today that Janet Hammond, MD, Ph.D., has joined the company as Vice President, Translational Medicine - Virology in Pharmaceutical Research and Early Development (pRED).
MADISON, Wis., March 22, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) announced today that their two-year collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY) to substantiate CDI's iCellÂ® Cardiomyocytes as a predictive tool for assessing the potential cardiotoxic effects of developing drug candidates was completed early and is now transitioning into a standard supply agreement.
INDIANAPOLIS and FORT BRAGG, N.C., Feb. 23, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received approval from the U.S.
SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc.
- Emitting flashes of light; glittering.